Espinoza Octavio, Chief Financial Officer of Ligand Pharmaceuticals (LGND), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his 61 total transactions. His selling activity totals approximately $5.52 million, concentrated in a series of large dispositions in early March 2026. On March 4 alone, Octavio executed ten separate open-market sales ranging from roughly $10,600 to $712,600, with combined proceeds exceeding $2.65 million. A week later, on March 11, he sold another $687,825 worth of shares. These sales were paired with option exercises (coded M) on the same dates, including exercises valued at $222,823 on March 11 and $93,993 plus $37,616 on March 4, indicating the sales likely converted vested options into cash.
The remaining transactions in the filing are largely mechanical or compensatory. Octavio received stock awards (coded A) valued at $0 on March 2 and February 14, 2026, and had shares withheld to cover tax obligations (coded F) on February 14–15, totaling roughly $1.47 million. A small "other" transaction (coded J) of $2,732 occurred on June 30, 2026, and two option exercises in late May 2026 brought in $99,966 combined. Notably, there are no recent purchases (coded P) in the data, and the only acquisition value across all filings is $23,898.83, which stems from option exercises rather than discretionary buying.
The pattern is unambiguous: Octavio has been a net seller of LGND stock throughout the period, with all discretionary activity pointing toward liquidation rather than accumulation. The March 2026 cluster of sales, executed over two separate days, represents the bulk of his realized value and suggests a deliberate reduction of his position. While the option exercises and tax-withholding transactions are routine for an executive, the absence of any open-market buys reinforces a bearish bias in his personal trading.
AI-assisted summary